Search Results - "Aalamian‐Mattheis, Maryam"

Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX‐AHF‐EU by Maggioni, Aldo P., López‐Sendón, José, Nielsen, Olav W., Hallén, Jonas, Aalamian‐Mattheis, Maryam, Wang, Yaqin, Ertl, Georg

“…Aim Serelaxin is a recombinant human relaxin‐2 hormone, which confers receptor‐mediated vasodilatation in a tissue‐specific fashion. The RELAX‐AHF‐EU study…”
Get full text

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial by Vogelmeier, Claus F, Gaga, Mina, Aalamian-Mattheis, Maryam, Greulich, Timm, Marin, Jose M, Castellani, Walter, Ninane, Vincent, Lane, Stephen, Nunez, Xavier, Patalano, Francesco, Clemens, Andreas, Kostikas, Konstantinos

“…Dual bronchodilation combining a long-acting β -agonist (LABA) and a long-acting muscarinic antagonist (LAMA) is the preferred choice of treatment recommended…”
Get full text

Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study by Kostikas, Konstantinos, Greulich, Timm, Mackay, Alexander J, Lossi, Nadine S, Aalamian-Mattheis, Maryam, Nunez, Xavier, Pagano, Veronica A, Patalano, Francesco, Clemens, Andreas, Vogelmeier, Claus F

“…The association between clinically relevant changes in patient-reported outcomes (PROs) and forced expiratory volume in 1 s (FEV1) in patients with chronic…”
Get full text

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study by Greulich, Timm, Kostikas, Konstantinos, Gaga, Mina, Aalamian-Mattheis, Maryam, Lossi, Nadine S, Patalano, Francesco, Nunez, Xavier, Pagano, Veronica A, Fogel, Robert, Vogelmeier, Claus F, Clemens, Andreas

“…COPD is a progressive disease characterized by exacerbations and a decline in health status and lung function. Clinically important deterioration (CID) is a…”
Get full text

Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING) by Marin, Jose M, Beeh, Kai M, Clemens, Andreas, Castellani, Walter, Schaper, Lennart, Saralaya, Dinesh, Gunstone, Anthony, Casamor, Ricard, Kostikas, Konstantinos, Aalamian-Mattheis, Maryam

“…Morning symptoms associated with COPD have a negative impact on patients' quality of life. Long-acting bronchodilators with rapid onset may relieve patients'…”
Get full text

Treatment response in COPD: does FEV 1 say it all? A post hoc analysis of the CRYSTAL study by Kostikas, Konstantinos, Greulich, Timm, Mackay, Alexander J, Lossi, Nadine S, Aalamian-Mattheis, Maryam, Nunez, Xavier, Pagano, Veronica A, Patalano, Francesco, Clemens, Andreas, Vogelmeier, Claus F

“…The association between clinically relevant changes in patient-reported outcomes (PROs) and forced expiratory volume in 1 s (FEV ) in patients with chronic…”
Get full text